2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
Aron Goldhirsch(European Institute of Oncology), Richard D. Gelber(Frontier Agriculture (United Kingdom)), Martine Piccart(Institut Jules Bordet), Evandro de Azambuja(Université Libre de Bruxelles), Marion Procter(Frontier Agriculture (United Kingdom)), Thomas Suter(University Hospital of Bern), Christian Jackisch(Sana Klinikum Offenbach), David Cameron(University of Edinburgh), Harald Weber(Roche (Switzerland)), Dominik Heinzmann(Roche (Switzerland)), Lissandra Dal Lago(Institut Jules Bordet), Eleanor McFadden(Frontier Agriculture (United Kingdom)), Mitch Dowsett(National Health Service), Michael Untch(Helios Hospital Berlin-Buch), Luca Gianni(IRCCS Ospedale San Raffaele), Richard H. Bell(Geelong Hospital), Claus-Henning Köhne(Klinikum Oldenburg), A. Vindevoghel, Michael Andersson(Rigshospitalet), Adrian Murray Brunt(Royal Stoke University Hospital), Douglas Otero-Reyes, Santai Song(307th Hospital of Chinese People’s Liberation Army), Ian Smith(Royal Marsden Hospital), Brian Leyland‐Jones(Sanford Research), José Baselga(Memorial Sloan Kettering Cancer Center)
Cited by 501
Abstract
Related Papers
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones et al.|New England Journal of Medicine|2005|5.1k